Q2 EPS Forecast for Alto Neuroscience Reduced by Analyst

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Analysts at William Blair lowered their Q2 2025 EPS estimates for shares of Alto Neuroscience in a research report issued to clients and investors on Thursday, May 15th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($0.55) per share for the quarter, down from their prior estimate of ($0.51). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience's Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.21) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.45) EPS, FY2026 earnings at ($1.98) EPS, FY2027 earnings at ($2.02) EPS, FY2028 earnings at ($2.91) EPS and FY2029 earnings at ($1.43) EPS.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright initiated coverage on shares of Alto Neuroscience in a report on Monday, April 7th. They issued a "buy" rating and a $10.00 price target on the stock. Wedbush reissued a "neutral" rating and set a $4.00 target price on shares of Alto Neuroscience in a report on Thursday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of "Moderate Buy" and an average price target of $15.40.

Alto Neuroscience Trading Up 5.0%

NYSE:ANRO opened at $2.55 on Monday. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $69.06 million, a PE ratio of -1.09 and a beta of 1.87. The firm's 50 day moving average is $2.37 and its 200 day moving average is $3.43. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $17.55.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.06.

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently bought and sold shares of ANRO. Armistice Capital LLC raised its holdings in Alto Neuroscience by 146.2% during the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company's stock valued at $3,456,000 after acquiring an additional 950,000 shares during the period. Marshall Wace LLP purchased a new position in shares of Alto Neuroscience during the 4th quarter valued at $3,542,000. Point72 Asset Management L.P. grew its position in shares of Alto Neuroscience by 73.1% during the 4th quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company's stock valued at $7,158,000 after purchasing an additional 714,461 shares in the last quarter. Woodline Partners LP grew its position in shares of Alto Neuroscience by 397.6% during the 4th quarter. Woodline Partners LP now owns 621,976 shares of the company's stock valued at $2,631,000 after purchasing an additional 496,976 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Alto Neuroscience by 198.1% during the 4th quarter. Northern Trust Corp now owns 587,135 shares of the company's stock valued at $2,484,000 after purchasing an additional 390,190 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.